SCHEDULE: Oaktree Reduces Indivior Stake to 7%

Sentiment:

Beneficial Ownership Amendment 13 November 2025 9:15 PM

Oaktree Capital Management and its affiliates have reduced their beneficial ownership in Indivior PLC to 7.0% through a series of share sales.

Worse than expectedA significant institutional investor, Oaktree Capital Management, has reduced its beneficial ownership in Indivior PLC from a higher percentage to 7.0%.The sale of nearly 2 million shares by a major holder over a short period could be interpreted negatively by the market, signaling a potential decrease in investor confidence or a strategic exit.

Summary

Oaktree Capital Management and its affiliated funds (the "Reporting Persons") have filed Amendment No. 4 to their Schedule 13D regarding their stake in Indivior PLC.
The Reporting Persons now collectively beneficially own 8,745,084 Ordinary Shares of Indivior PLC, representing 7.0% of the company's outstanding shares.
This percentage is calculated based on 124,853,897 Ordinary Shares outstanding as of October 1, 2025, as disclosed in Indivior's Form 10-Q filed on October 30, 2025.
Within the 60 days prior to the filing, Oaktree entities disposed of a total of 1,946,969 Ordinary Shares through multiple sales transactions.
Sale prices for these dispositions ranged from $24.53 to $31.17 per share, with the latest reported sale occurring on November 13, 2025.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative for Indivior PLC due to a significant institutional investor reducing its stake, which can signal a lack of conviction or a strategic exit, potentially impacting investor confidence and share price.

Negatives

A significant institutional investor, Oaktree Capital Management, has reduced its stake in Indivior PLC from a previously higher percentage (implied by "Amendment No. 4" and the sales activity) to 7.0%.
The sale of nearly 2 million shares by a major holder could signal a lack of conviction or a strategic exit, potentially putting downward pressure on the stock price.

Future Outlook

Industry Context

This filing reflects a portfolio adjustment by a major institutional investor in the pharmaceutical sector. While specific reasons for Oaktree's reduction in stake are not disclosed, such moves can sometimes be influenced by broader market trends, sector-specific outlooks, or a re-evaluation of the investment thesis for Indivior PLC within Oaktree's portfolio strategy.

Stakeholder Impact

Shareholders: May experience negative sentiment and potential downward pressure on share price due to a large investor reducing its stake.
Potential Investors: May view the reduction in stake by Oaktree as a cautionary signal, influencing their investment decisions.

Key Dates

Date	Description
2024-10-02	Original Schedule 13D filing date.
2024-11-07	Amendment No. 1 filed.
2024-12-18	Amendment No. 2 filed.
2025-03-04	Amendment No. 3 filed.
2025-10-01	Date as of which 124,853,897 Ordinary Shares were outstanding, per Issuer's 10-Q.
2025-10-14	First reported share sale by Oaktree (50,000 shares at $24.53).
2025-10-16	Share sale by Oaktree (49,760 shares at $24.70).
2025-10-30	Share sale by Oaktree (830,000 shares at $29.32) and date of Issuer's Form 10-Q filing.
2025-10-31	Share sale by Oaktree (150,000 shares at $29.07).
2025-11-03	Share sale by Oaktree (105,000 shares at $31.17).
2025-11-10	Date of event requiring this filing (share sale of 179,768 shares at $30.92).
2025-11-11	Share sale by Oaktree (306,553 shares at $30.89).
2025-11-12	Share sale by Oaktree (240,895 shares at $30.12).
2025-11-13	Latest reported share sale by Oaktree (34,993 shares at $30.12) and filing signature date.

Recommendation

hold

While a major institutional investor reducing its stake can be a negative signal, the filing itself does not provide fundamental reasons for the sales, which could be due to portfolio rebalancing rather than a negative outlook on Indivior's core business. Investors should hold and monitor future filings and company performance for more definitive insights before making a 'buy' or 'sell' decision.

Keywords

Indivior PLC, Oaktree Capital Management, Schedule 13D, Beneficial Ownership, Share Sales, Institutional Investor, Equity Stake, Pharmaceuticals, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.